Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents
Autore:
Griebel, G; Perrault, G; Sanger, DJ;
Indirizzi:
Synthelabo Rech, CNS Res Dept, F-92220 Bagneux, France Synthelabo Rech Bagneux France F-92220 Res Dept, F-92220 Bagneux, France
Titolo Testata:
JOURNAL OF PSYCHOPHARMACOLOGY
fascicolo: 4, volume: 12, anno: 1998,
pagine: 356 - 365
SICI:
0269-8811(199812)12:4<356:LAEONH>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEFENSE TEST BATTERY; ELEVATED PLUS-MAZE; RECEPTOR LIGANDS; PHARMACOLOGICAL PROFILES; INSOMNIAC PATIENTS; SWISS-WEBSTER; ZOPICLONE; ZOLPIDEM; DRUGS; ANXIETY;
Keywords:
anxiety; conflict procedures; hypnotics; SX-3228; triazolam; zaleplon; zolpidem; zopiclone;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Griebel, G Synthelaboeux,h, CNS Res Dept, 31 Ave Paul Vaillant Couturier, F-92220 Bagn Synthelabo Rech 31 Ave Paul Vaillant Couturier Bagneux FranceF-92220
Citazione:
G. Griebel et al., "Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents", J PSYCHOPH, 12(4), 1998, pp. 356-365

Abstract

The present experiments compared the anxiolytic-like effects of the benzodiazepine (BZD) hypnotic triazolam with those of four non-BZD hypnotics including one non-selective (zopiclone) and three omega(1)-BZD selective (zolpidem, zaleplon and SX-3228) receptor ligands, in classical animal models including conflict tests (punished lever pressing and punished drinking tests in rats) and exploratory models (elevated plus-maze test in rats and light/dark choice test in mice), and a recently developed mouse defence test battery (MDTB) which has been validated for the screening of anxiolytic drugs. Results from both conflict procedures showed that zopiclone (0.3-10 mg/kg) produced anxiolytic-like effects comparable to those of triazolam (0.1-3 mg/kg), whereas the selective omega(1)-BZD receptor hypnotics zolpidem (0.3-3mg/kg), zaleplon (0.1-3 mg/kg) and SX-3228 (0.1-1 mg/kg) displayed weaker and/or non-specific anxiolytic-like effects. Similarly, in the light/dark test in mice, zolpidem (0.1-1 mg/kg), zaleplon (0.3-10 mg/kg) and SX-3228 (0.03-0.3 mg/kg) showed a reduced potential to produce anxiolytic-like effects as compared to the non-selective omega-BZD receptor hypnotics triazolam (0.03-1 mg/kg) and zopiclone (1-30 mg/kg). In the elevated plus-maze test, zopiclone (1-10 mg/kg), zolpidem (0.1-1 mg/kg), zaleplon (0.3-3 mg/kg) and SX-3228 (0.1-1 mg/kg) displayed anxiolytic-like activity at doses close to those producing behavioural impairment, whereas triazolam (0.03-1 mg/kg) exhibited anxiolytic-like effects over a wide dose range in the absence of decreases in general activity. In the MDTB, zaleplon (0.3-10 mg/kg) decreased all defensive responses, a profile which was similar to that of triazolam (0.03-1 mg/kg), while zopiclone (1-30 mg/kg), zolpidem (0.3-10 mg/kg) and SX-3228 (0.03-1 mg/kg) had fewer effects on defensive behaviours with severaleffects occurring only at motor-impairing doses. Taken together, these results demonstrate that, although selective omega(1)-BZD receptor hypnotics display anxiolytic-like activity, the effects are generally weaker than those observed with non-selective omega-BZD receptor selective hypnotics such as triazolam or zopiclone. In particular, the anxiety-reducing potential of the omega(1)-BZD receptor selective compounds is limited to certain anxietymeasures and may be confounded and/or masked by behavioural suppression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 13:29:58